34 related articles for article (PubMed ID: 29132550)
1. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
2. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.
Vanden Berg RNW; Zilli T; Achard V; Dorff T; Abern M
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):702-711. PubMed ID: 37422523
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
4. Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer.
Tian Y; Mao Y; Tang Z; Hu M
Technol Cancer Res Treat; 2023; 22():15330338231216011. PubMed ID: 38105493
[TBL] [Abstract][Full Text] [Related]
5. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive radical prostatectomy or radiation therapy for metastases prostate cancer: Evidence from meta-analysis.
Peng Z; Huang A
Medicine (Baltimore); 2022 Sep; 101(38):e30671. PubMed ID: 36197186
[TBL] [Abstract][Full Text] [Related]
7. Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
Tsaur I; Blaheta RA; Dotzauer R; Brandt MP; Gandaglia G; Sinescu I; Mirvald C; Olivier J; Surcel C;
World J Urol; 2023 Aug; 41(8):2077-2090. PubMed ID: 36183289
[TBL] [Abstract][Full Text] [Related]
8. Advancements in the treatment of metastatic hormone-sensitive prostate cancer.
Li H; Zhang M; Wang X; Liu Y; Li X
Front Oncol; 2022; 12():913438. PubMed ID: 36059610
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis.
Mao Y; Hu M; Yang G; Gao E; Xu W
World J Surg Oncol; 2022 Aug; 20(1):255. PubMed ID: 35945562
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis.
Cheng B; Ye S; Bai P
World J Surg Oncol; 2021 May; 19(1):160. PubMed ID: 34051809
[TBL] [Abstract][Full Text] [Related]
11. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive treatment strategies for de novo metastatic prostate cancer.
Connor MJ; Shah TT; Horan G; Bevan CL; Winkler M; Ahmed HU
Nat Rev Clin Oncol; 2020 Mar; 17(3):168-182. PubMed ID: 31712648
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor cytoreduction in metastatic prostate cancer.
Sow Y; Sow O; Fall B; Sine B; Sarr A; Zé Ondo C; Diao B; Ndoye AK; Ba M
Res Rep Urol; 2019; 11():137-142. PubMed ID: 31192170
[No Abstract] [Full Text] [Related]
14. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer.
Han G; Zhang X; Liu P; Yu Q; Li Z; Yu Q; Wei X
Int J Oncol; 2018 Nov; 53(5):2056-2066. PubMed ID: 30132513
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis.
Sheng MX; Wan LL; Liu CM; Liu CX; Chen SS
Kaohsiung J Med Sci; 2017 Dec; 33(12):609-615. PubMed ID: 29132550
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis.
Sheng M; Guo S; Liu C
World J Surg Oncol; 2021 Dec; 19(1):345. PubMed ID: 34903228
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
18. Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?
Sheng M; Wan L; Liu C; Liu C
Singapore Med J; 2018 Nov; 59(11):584-589. PubMed ID: 30246213
[TBL] [Abstract][Full Text] [Related]
19. [Cytoreductive, radical prostatectomy in metastatic prostate cancer].
Chaloupka M; Herlemann A; Spek A; Gratzke C; Stief C
Urologe A; 2017 Nov; 56(11):1430-1434. PubMed ID: 28983651
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
